QL2107 Injection

DRUG2 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

CLDN18.2-positive Advanced Biliary Tract CancerGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma

Phase 2

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Not yet recruitingNCT06942767

Qilu Pharmaceutical Co., Ltd.Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Start: 2025-06-30End: 2028-03-31Target: 100Updated: 2025-04-27

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

Not yet recruitingNCT07151872

Qilu Pharmaceutical Co., Ltd.CLDN18.2-positive Advanced Biliary Tract Cancer

Start: 2025-09-30End: 2026-10-31Target: 120Updated: 2025-09-03